Ocular Therapeutix (OCUL) – Hot FDA News
-
UPDATE: Ocular Therapeutix (OCUL) Falls 14% After Reporting Interim 7-month Data from Phase 1 Clinical Trial of OTX-TKI
-
Ocular Therapeutix (OCUL) Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
-
-
-
-
-
-
Back to OCUL Stock Lookup